Can Schlafen 11 Help to Stratify Ovarian Cancer Patients
Treated with DNA-Damaging Agents?

J 2022

Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Lucie EHRLICHOVÁ, Květoslava MATULOVÁ, Eliška GAZÁRKOVÁ et. al.

Basic information

Original name

Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

Authors

BEDNAŘÍKOVÁ, Markéta (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Lucie EHRLICHOVÁ (203 Czech Republic, belonging to the institution), Květoslava MATULOVÁ (203 Czech Republic, belonging to the institution), Eliška GAZÁRKOVÁ (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution) and Vít WEINBERGER (203 Czech Republic, guarantor, belonging to the institution)

Edition

Cancers, Basel, MDPI, 2022, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00129670

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers14102353

UT WoS

000803347900001

Keywords in English

SLFN11; ovarian cancer; high-grade serous carcinoma; DNA-damaging agents; PARPi; chemoresistance

Abstract

V originále

Platinum-based chemotherapy has been the cornerstone of systemic treatment in ovarian cancer. Since no validated molecular predictive markers have been identified yet, the response to platinum-based chemotherapy has been evaluated clinically, based on platinum-free interval. The new promising marker Schlafen 11 seems to correlate with sensitivity or resistance to DNA-damaging agents, including platinum compounds or PARP inhibitors in various types of cancer. We provide background information about the function of Schlafen 11, its evaluation in tumor tissue, and its prevalence in ovarian cancer. We discuss the current evidence of the correlation of Schlafen 11 expression in ovarian cancer with treatment outcomes and the potential use of Schlafen 11 as the key predictive and prognostic marker that could help to better stratify ovarian cancer patients treated with platinum-based chemotherapy or PARP inhibitors. We also provide perspectives on future directions in the research on this promising marker.

Links

NU21-03-00306, research and development project

Name: Komplexní genomové profilování u pacientek s karcinomem ovaria léčených platinovými deriváty: identifikace prediktivních biomarkerů a ověření využitelnosti precizní onkologie

Investor: Ministry of Health of the CR, Comprehensive genomic profiling in ovarian cancer patients treated with platinumbased chemotherapy: identification of predictive biomarkers and evaluation of the potential of precision oncology approach, Subprogram 1 - standard

Citovat

BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Lucie EHRLICHOVÁ, Květoslava MATULOVÁ, Eliška GAZÁRKOVÁ, Luboš MINÁŘ and Vít WEINBERGER. Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents? Cancers. Basel: MDPI, 2022, vol. 14, No 10, p. 1-13. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers14102353.

@article{1858546,
   author = {Bednaříková, Markéta and Hausnerová, Jitka and Ehrlichová, Lucie and Matulová, Květoslava and Gazárková, Eliška and Minář, Luboš and Weinberger, Vít},
   article_location = {Basel},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/cancers14102353},
   keywords = {SLFN11; ovarian cancer; high-grade serous carcinoma; DNA-damaging agents; PARPi; chemoresistance},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?},
   url = {https://www.mdpi.com/2072-6694/14/10/2353},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 1858546
AU  - Bednaříková, Markéta - Hausnerová, Jitka - Ehrlichová, Lucie - Matulová, Květoslava - Gazárková, Eliška - Minář, Luboš - Weinberger, Vít
PY  - 2022
TI  - Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?
JF  - Cancers
VL  - 14
IS  - 10
SP  - 1-13
EP  - 1-13
PB  - MDPI
SN  - 20726694
KW  - SLFN11
KW  - ovarian cancer
KW  - high-grade serous carcinoma
KW  - DNA-damaging agents
KW  - PARPi
KW  - chemoresistance
UR  - https://www.mdpi.com/2072-6694/14/10/2353
N2  - Platinum-based chemotherapy has been the cornerstone of systemic treatment in ovarian cancer. Since no validated molecular predictive markers have been identified yet, the response to platinum-based chemotherapy has been evaluated clinically, based on platinum-free interval. The new promising marker Schlafen 11 seems to correlate with sensitivity or resistance to DNA-damaging agents, including platinum compounds or PARP inhibitors in various types of cancer. We provide background information about the function of Schlafen 11, its evaluation in tumor tissue, and its prevalence in ovarian cancer. We discuss the current evidence of the correlation of Schlafen 11 expression in ovarian cancer with treatment outcomes and the potential use of Schlafen 11 as the key predictive and prognostic marker that could help to better stratify ovarian cancer patients treated with platinum-based chemotherapy or PARP inhibitors. We also provide perspectives on future directions in the research on this promising marker.
ER  -

BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Lucie EHRLICHOVÁ, Květoslava MATULOVÁ, Eliška GAZÁRKOVÁ, Luboš MINÁŘ and Vít WEINBERGER. Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents? \textit{Cancers}. Basel: MDPI, 2022, vol.~14, No~10, p.~1-13. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers14102353.

Detailed Information on Publication Record